Video

Expert forum on prostate cancer survivorship: Individualized care

Author(s):

Urology Times staff

“We certainly need to move away from a model of care that is follow up driven by tumor markers or imaging alone,” says Netty Kinsella, RN, MSc, PhD.

In this video, Netty Kinsella, RN, MSc, PhD, and Jai Seth, MD, BSc, MSc, discuss the importance of individualized care in prostate cancer survivorship. This discussion is part of a larger forum on prostate cancer survivorship with Marta Skrodzka, MD, PhD, FEBU, FECSM, FEAA. Skrodzka is a consultant urologist and Seth is a urology consultant at St George’s University Hospital, and Kinsella is a uro-oncology nurse consultant at the Royal Marsden NHS Foundation Trust in London, United Kingdom.

Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Related Content
Radioligand therapy shows promising safety in patients with mCRPC
March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke
The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke
"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC
March 4th 2025

Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC

Hannah Clarke
The median OS was 34 months with 177Lu-PSMA-617 plus enzalutamide compared with 26 months with enzalutamide alone.
FDA updates in urology: February 2025
March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from February 2025.
© 2025 MJH Life Sciences

All rights reserved.